ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ertugliflozin

Also written as “Ertugliflozin 5 mg”, “Ertugliflozin” and “Ertugliflozin 15 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Fatty Liver · Renal Insufficiency, led by 3 companies.

Drug pageErtugliflozin: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 7, 201322 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only200 open or runningphase 3since Oct 7, 2013Oct 1, 2009none ahead
Getz Pharma11 open or runningphase 4since Nov 18, 2022Nov 18, 2022none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Dec 3, 2025Dec 3, 2025none ahead

Also a collaborator on its studies: Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Getz Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2022First study: phase 4 study in Fatty LiverFirst studyNCT05644717 · 164 planned · Pakistan

TargetBeta

SLC5A2 →read by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
empagliflozinruleBoehringer Ingelheimphase 4142
dapagliflozinAstraZenecaphase 4133
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

The one study Getz Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05644717Fatty Liver · Pakistan4RecruitingNov 1, 2025164

How it is read

Names in the registry

  • “Ertugliflozin 5 mg”, 10 entries
  • “Ertugliflozin”, 8 entries
  • “Ertugliflozin 15 mg”, 5 entries
  • “Ertugliflozin 10 mg”, 4 entries
  • “Ertugliflozin 1 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.